Form 8-K - Current report:
SEC Accession No. 0001013762-23-003933
Filing Date
2023-10-16
Accepted
2023-10-16 06:16:44
Documents
15
Period of Report
2023-10-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea186779-8k_moonlake.htm   iXBRL 8-K 28846
2 PRESS RELEASE, DATED OCTOBER 15, 2023 ea186779ex99-1_moonlake.htm EX-99.1 45031
3 GRAPHIC image_001.jpg GRAPHIC 10636
4 GRAPHIC ex99-1_001.jpg GRAPHIC 10560
  Complete submission text file 0001013762-23-003933.txt   302524

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mltx-20231015.xsd EX-101.SCH 3021
6 XBRL LABEL FILE mltx-20231015_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE mltx-20231015_pre.xml EX-101.PRE 22363
9 EXTRACTED XBRL INSTANCE DOCUMENT ea186779-8k_moonlake_htm.xml XML 3297
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 231326158
SIC: 2834 Pharmaceutical Preparations